Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission

OBJECTIVE: To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid leukemia in first remission. METHOD: Twenty patients who received auto-HSCT at our center between January 2014 and January 2021 were retrospectively rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Juan, Liu, Li, Ma, Runzhi, Pang, Aiming, Yang, Donglin, Chen, Xin, Wei, Jialin, He, Yi, Zhang, Rongli, Zhai, Weihua, Ma, Qiaoling, Jiang, Erlie, Han, Mingzhe, Zhou, Jiaxi, Feng, Sizhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623918/
https://www.ncbi.nlm.nih.gov/pubmed/36316734
http://dx.doi.org/10.1186/s12935-022-02750-4
_version_ 1784822113588215808
author Chen, Juan
Liu, Li
Ma, Runzhi
Pang, Aiming
Yang, Donglin
Chen, Xin
Wei, Jialin
He, Yi
Zhang, Rongli
Zhai, Weihua
Ma, Qiaoling
Jiang, Erlie
Han, Mingzhe
Zhou, Jiaxi
Feng, Sizhou
author_facet Chen, Juan
Liu, Li
Ma, Runzhi
Pang, Aiming
Yang, Donglin
Chen, Xin
Wei, Jialin
He, Yi
Zhang, Rongli
Zhai, Weihua
Ma, Qiaoling
Jiang, Erlie
Han, Mingzhe
Zhou, Jiaxi
Feng, Sizhou
author_sort Chen, Juan
collection PubMed
description OBJECTIVE: To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid leukemia in first remission. METHOD: Twenty patients who received auto-HSCT at our center between January 2014 and January 2021 were retrospectively reviewed. RESULTS: Until last follow-up, three patients in the cohort were dead due to relapse. The estimated 1-year and 5-year overall survival were 95.00% ± 4.87% and 83.82% ± 8.58%, respectively. The estimated 5-year RFS and CIR (cumulative incidence of relapse) were 85.00% ± 7.98% and 15.00% ±7.98%, respectively. CONCLUSION: The outcome of auto-HSCT in patients with favorable-risk acute myeloid leukemia in first remission was excellent and auto-HSCT could be an effective treatment for these patients.
format Online
Article
Text
id pubmed-9623918
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96239182022-11-02 Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission Chen, Juan Liu, Li Ma, Runzhi Pang, Aiming Yang, Donglin Chen, Xin Wei, Jialin He, Yi Zhang, Rongli Zhai, Weihua Ma, Qiaoling Jiang, Erlie Han, Mingzhe Zhou, Jiaxi Feng, Sizhou Cancer Cell Int Research OBJECTIVE: To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid leukemia in first remission. METHOD: Twenty patients who received auto-HSCT at our center between January 2014 and January 2021 were retrospectively reviewed. RESULTS: Until last follow-up, three patients in the cohort were dead due to relapse. The estimated 1-year and 5-year overall survival were 95.00% ± 4.87% and 83.82% ± 8.58%, respectively. The estimated 5-year RFS and CIR (cumulative incidence of relapse) were 85.00% ± 7.98% and 15.00% ±7.98%, respectively. CONCLUSION: The outcome of auto-HSCT in patients with favorable-risk acute myeloid leukemia in first remission was excellent and auto-HSCT could be an effective treatment for these patients. BioMed Central 2022-10-31 /pmc/articles/PMC9623918/ /pubmed/36316734 http://dx.doi.org/10.1186/s12935-022-02750-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Juan
Liu, Li
Ma, Runzhi
Pang, Aiming
Yang, Donglin
Chen, Xin
Wei, Jialin
He, Yi
Zhang, Rongli
Zhai, Weihua
Ma, Qiaoling
Jiang, Erlie
Han, Mingzhe
Zhou, Jiaxi
Feng, Sizhou
Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
title Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
title_full Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
title_fullStr Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
title_full_unstemmed Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
title_short Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
title_sort outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623918/
https://www.ncbi.nlm.nih.gov/pubmed/36316734
http://dx.doi.org/10.1186/s12935-022-02750-4
work_keys_str_mv AT chenjuan outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT liuli outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT marunzhi outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT pangaiming outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT yangdonglin outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT chenxin outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT weijialin outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT heyi outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT zhangrongli outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT zhaiweihua outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT maqiaoling outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT jiangerlie outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT hanmingzhe outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT zhoujiaxi outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission
AT fengsizhou outcomeofautologousstemcelltransplantationinpatientswithfavorableriskacutemyeloidleukemiainfirstremission

Ejemplares similares